Literature DB >> 18227853

Receptors for complement C5a. The importance of C5aR and the enigmatic role of C5L2.

Hyun Lee1, Peter L Whitfeld, Charles R Mackay.   

Abstract

Complement component C5a is one of the most potent inflammatory chemoattractants and has been implicated in the pathogenesis of numerous inflammatory diseases. C5a binds two receptors, C5aR and C5L2. Most of the C5a functional effects occur through C5aR, and the pharmaceutical industry has focused on this receptor for the development of new anti-inflammatory therapies. We used a novel approach to generate and test therapeutics that target C5aR. We created human C5aR knock-in mice, and used neutrophils from these to immunize wild-type mice. This yielded high-affinity blocking mAbs to human C5aR. We tested these anti-human C5aR mAbs in mouse models of inflammation, using the human C5aR knock-in mice. These antibodies completely prevented disease onset and were also able to reverse established disease in the K/B x N arthritis model. The physiological role of the other C5a receptor, C5L2 is still unclear, and our studies with blocking mAbs to human C5L2 have failed to demonstrate a clear functional role in signaling to C5a. The development of effective mAbs to human C5aR is an alternative approach to drug development, for this highly attractive target.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18227853     DOI: 10.1038/sj.icb.7100166

Source DB:  PubMed          Journal:  Immunol Cell Biol        ISSN: 0818-9641            Impact factor:   5.126


  59 in total

1.  Neisseria meningitidis and Escherichia coli are protected from leukocyte phagocytosis by binding to erythrocyte complement receptor 1 in human blood.

Authors:  Ole-Lars Brekke; Bernt Christian Hellerud; Dorte Christiansen; Hilde Fure; Albert Castellheim; Erik Waage Nielsen; Anne Pharo; Julie Katrine Lindstad; Grethe Bergseth; Graham Leslie; John D Lambris; Petter Brandtzaeg; Tom Eirik Mollnes
Journal:  Mol Immunol       Date:  2011-08-11       Impact factor: 4.407

2.  Do MDL-1⁺ cells play a broad role in acute inflammation?

Authors:  Peter A Ward
Journal:  J Clin Invest       Date:  2011-10-17       Impact factor: 14.808

Review 3.  Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.

Authors:  T V Arumugam; T M Woodruff; J D Lathia; P K Selvaraj; M P Mattson; S M Taylor
Journal:  Neuroscience       Date:  2008-07-12       Impact factor: 3.590

Review 4.  Pleiotropic regulations of neutrophil receptors response to sepsis.

Authors:  Huafeng Zhang; Bingwei Sun
Journal:  Inflamm Res       Date:  2016-09-30       Impact factor: 4.575

5.  A New Approach for the Treatment of Arthritis in Mice with a Novel Conjugate of an Anti-C5aR1 Antibody and C5 Small Interfering RNA.

Authors:  Gaurav Mehta; Robert I Scheinman; V Michael Holers; Nirmal K Banda
Journal:  J Immunol       Date:  2015-04-27       Impact factor: 5.422

6.  C5a receptor-deficient dendritic cells promote induction of Treg and Th17 cells.

Authors:  Donald J Weaver; Edimara S Reis; Manoj K Pandey; Gabriele Köhl; Nathaniel Harris; Craig Gerard; Jörg Köhl
Journal:  Eur J Immunol       Date:  2010-03       Impact factor: 5.532

7.  Complement c5a generation by staphylococcal biofilms.

Authors:  Ashley E Satorius; Jacob Szafranski; Derek Pyne; Mahesh Ganesan; Michael J Solomon; Duane W Newton; David M Bortz; John G Younger
Journal:  Shock       Date:  2013-04       Impact factor: 3.454

8.  C5L2 Regulates DMP1 Expression during Odontoblastic Differentiation.

Authors:  F Chmilewsky; R Liang; M Kanazawa; I About; L F Cooper; A George
Journal:  J Dent Res       Date:  2019-01-31       Impact factor: 6.116

9.  Complement activation on neutrophils initiates endothelial adhesion and extravasation.

Authors:  Antonina Akk; Luke E Springer; Lihua Yang; Samantha Hamilton-Burdess; John D Lambris; Huimin Yan; Ying Hu; Xiaobo Wu; Dennis E Hourcade; Mark J Miller; Christine T N Pham
Journal:  Mol Immunol       Date:  2019-09-19       Impact factor: 4.407

Review 10.  Functions of C5a receptors.

Authors:  Peter A Ward
Journal:  J Mol Med (Berl)       Date:  2009-02-03       Impact factor: 4.599

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.